424 related articles for article (PubMed ID: 16955982)
21. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.
Auriacombe S; Pere JJ; Loria-Kanza Y; Vellas B
Curr Med Res Opin; 2002; 18(3):129-38. PubMed ID: 12094822
[TBL] [Abstract][Full Text] [Related]
22. [Acetylcholinesterase inhibitors for dementia--an update].
Anghelescu I; Heuser I
MMW Fortschr Med; 2007 May; 149 Suppl 2():76-8. PubMed ID: 17724973
[TBL] [Abstract][Full Text] [Related]
23. Dementia medications in palliative care #174.
Morrison LJ; Liao S
J Palliat Med; 2008 May; 11(4):634-5. PubMed ID: 18454618
[No Abstract] [Full Text] [Related]
24. Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model.
Van Dam D; Abramowski D; Staufenbiel M; De Deyn PP
Psychopharmacology (Berl); 2005 Jun; 180(1):177-90. PubMed ID: 15654502
[TBL] [Abstract][Full Text] [Related]
25. Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials?
Ehret MJ; Chamberlin KW
Clin Ther; 2015 Aug; 37(8):1604-16. PubMed ID: 26122885
[TBL] [Abstract][Full Text] [Related]
26. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.
Takeda A; Loveman E; Clegg A; Kirby J; Picot J; Payne E; Green C
Int J Geriatr Psychiatry; 2006 Jan; 21(1):17-28. PubMed ID: 16323253
[TBL] [Abstract][Full Text] [Related]
27. Pharmacologic treatment options in Alzheimer's disease: optimizing disease management.
Aisen PS
J Am Acad Nurse Pract; 2005 Mar; Suppl():5-7. PubMed ID: 16033023
[TBL] [Abstract][Full Text] [Related]
28. Antidementia drug use among community-dwelling individuals with Alzheimer's disease in Finland: a nationwide register-based study.
Taipale H; Tanskanen A; Koponen M; Tolppanen AM; Tiihonen J; Hartikainen S
Int Clin Psychopharmacol; 2014 Jul; 29(4):216-23. PubMed ID: 24608822
[TBL] [Abstract][Full Text] [Related]
29. Realistic expectations for treatment success in Alzheimer's disease.
Geldmacher DS; Frolich L; Doody RS; Erkinjuntti T; Vellas B; Jones RW; Banerjee S; Lin P; Sano M
J Nutr Health Aging; 2006; 10(5):417-29. PubMed ID: 17066215
[TBL] [Abstract][Full Text] [Related]
30. Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.
Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
Int J Technol Assess Health Care; 2002; 18(3):497-507. PubMed ID: 12391943
[TBL] [Abstract][Full Text] [Related]
31. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.
Kaduszkiewicz H; Zimmermann T; Beck-Bornholdt HP; van den Bussche H
BMJ; 2005 Aug; 331(7512):321-7. PubMed ID: 16081444
[TBL] [Abstract][Full Text] [Related]
32. Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
Prescrire Int; 2006 Jun; 15(83):103-6. PubMed ID: 16764099
[TBL] [Abstract][Full Text] [Related]
33. [Cholinesterase inhibitor therapy in long term care settings].
Vantelon C; Gilbert S; Kerneis S; Wolmark Y; Legrain S; Kergoat MJ
Rev Med Interne; 2006 Aug; 27(8):588-94. PubMed ID: 16806591
[TBL] [Abstract][Full Text] [Related]
34. Review of the validated HPLC and LC-MS/MS methods for determination of drugs used in clinical practice for Alzheimer's disease.
Ponnayyan Sulochana S; Sharma K; Mullangi R; Sukumaran SK
Biomed Chromatogr; 2014 Nov; 28(11):1431-90. PubMed ID: 24515838
[TBL] [Abstract][Full Text] [Related]
35. Understanding the latest advances in pharmacologic interventions for Alzheimer's disease.
van Dyck CH
CNS Spectr; 2004 Jul; 9(7 Suppl 5):24-8. PubMed ID: 15241297
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials.
Kavirajan H; Schneider LS
Lancet Neurol; 2007 Sep; 6(9):782-92. PubMed ID: 17689146
[TBL] [Abstract][Full Text] [Related]
37. Anti-Alzheimer drugs: life-threatening adverse effects.
Prescrire Int; 2007 Feb; 16(87):16. PubMed ID: 17326275
[TBL] [Abstract][Full Text] [Related]
38. Evidence-based pharmacotherapy of Alzheimer's disease.
Evans JG; Wilcock G; Birks J
Int J Neuropsychopharmacol; 2004 Sep; 7(3):351-69. PubMed ID: 15228642
[TBL] [Abstract][Full Text] [Related]
39. New drugs for Alzheimer's disease in Japan.
Takeda M; Tanaka T; Okochi M
Psychiatry Clin Neurosci; 2011 Aug; 65(5):399-404. PubMed ID: 21851448
[No Abstract] [Full Text] [Related]
40. Drug therapy of dementia in elderly patients. A review.
Olsen CE; Poulsen HD; Lublin HK
Nord J Psychiatry; 2005; 59(2):71-7. PubMed ID: 16195103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]